<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26312724</article-id>
      <article-id pub-id-type="pmc">4540558</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20152563</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Rendu-Osler-Weber syndrome: dermatological approach<xref ref-type="fn" rid="fn01">*</xref></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Barbosa</surname>
            <given-names>Aline Blanco</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hans Filho</surname>
            <given-names>G&#xFC;nter</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vicari</surname>
            <given-names>Carolina Faria dos Santos</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Medeiros</surname>
            <given-names>Marcelo Zanolli</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Couto</surname>
            <given-names>Da&#xED;ne Vargas</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Takita</surname>
            <given-names>Luiz Carlos</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label>Hospital S&#xE3;o Juli&#xE3;o - Campo Grande (MS), Brazil.</aff>
      <aff id="aff02"><label>2</label>Universidade Federal do Mato Grosso do Sul (UFMS) - Campo
Grande (MS), Brazil.</aff>
      <author-notes>
        <corresp id="c01">MAILING ADDRESS: Aline Blanco Barbosa, Av. Sen. Felinto M&#xFC;ller, S/N,
Vila Ipiranga, 79090-190 - Campo Grande - MS. Brazil. E-mail:
<email>alibbarbosa@yahoo.com.br</email></corresp>
        <fn fn-type="conflict">
          <p>Conflict of Interest: None.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <volume>90</volume>
      <issue>3 Suppl 1</issue>
      <fpage>226</fpage>
      <lpage>228</lpage>
      <history>
        <date date-type="received">
          <day>21</day>
          <month>2</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>01</day>
          <month>7</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2015 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>The Rendu-Osler-Weber syndrome is a rare systemic fibrovascular dysplasia, recognized
by mucocutaneous telangiectasias, arteriovenous malformations, epistaxis and family
history. Recurrent bleeding, hypoxemia, congestive heart failure, portosystemic
encephalopathy, and symptoms related to angiodysplasia of the central nervous system
may occur. Since the treatment is based on supportive measures, early recognition is
of utmost importance. This article reports the case of a 53-year-old male patient who
presented telangiectasias on fingers, oral cavity and nasal mucosa for 10 years, with
a history of recurrent epistaxis of varying severity since childhood. Mother, sister
and daughter have similar lesions.</p>
      </abstract>
      <kwd-group>
        <kwd>Epistaxis</kwd>
        <kwd>Genetics</kwd>
        <kwd>Telangiectasia</kwd>
        <kwd>hereditary hemorrhagic</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>The Rendu-Osler-Weber syndrome, also known as Hereditary Hemorrhagic Telangiectasia
(HHT) is a rare systemic fibrovascular dysplasia, characterized by recurrent epistaxis,
mucocutaneous telangiectasias, arteriovenous malformations (AVMs) in different organs
and family history.</p>
      <p>Its incidence is 1-2/100.000 homogeneously distributed by race and sex. It has autosomal
dominant transmission and high degree of penetrance, but there is no family history in
around 20% of cases.<sup><xref rid="r01" ref-type="bibr">1</xref></sup></p>
      <p>Mutations in two genes are considered as responsible for the majority of cases: endoglin
(ENG) located on chromosome 9q33-q34 and activin receptor-like kinase (ALK1) located on
chromosome 12q13.<sup><xref rid="r02" ref-type="bibr">2</xref></sup></p>
      <p>ENG mutations are observed in HHT type 1, phenotype responsible for 40% of pulmonary
AVMs whereas mutations of ALK1 are observed in HHT type 2, leading to lower incidence of
these AVMs (14%) associated with milder forms and late onset of the disease.<sup><xref rid="r03" ref-type="bibr">3</xref></sup></p>
      <p>The mutated genes encode proteins that modulate transforming growth factor beta (TGF-&#x3B2;),
which stimulates vascular endothelial growth factor (VEGF) production and plays a key
role in angiogenesis.<sup><xref rid="r04" ref-type="bibr">4</xref></sup></p>
      <p>Diagnosis is based on the Cura&#xE7;ao criteria:<sup><xref rid="r05" ref-type="bibr">5</xref></sup></p>
      <p>1) <underline>Epistaxis</underline> - spontaneous, recurrent nosebleeds;</p>
      <p>2) <underline>Telangiectasias</underline> - multiple, at characteristic sites (lips,
oral cavity, fingers, nose);</p>
      <p>3) <underline>Visceral lesions</underline> - such as gastrointestinal telangiectasias
(with or without bleeding), pulmonary AVM, hepatic AVM, cerebral AVM, spinal AVM;
and</p>
      <p>4) <underline>Family history</underline> - a first-degree relative with HHT.</p>
      <p>Three criteria indicate a definite diagnosis of the disorder; two a possible or
suspected case.</p>
      <p>The treatment is only palliative, with no consensus on the best treatment option. It is
essential to promote control of the disease as long as possible.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>Male patient, 53 years old, presented vegetating plaque on the back of the tongue and
telangiectasias on the lips, gums, palate, oral and nasal mucosa as well as on fingers
for 10 years (<xref ref-type="fig" rid="f01">Figure 1</xref>). He complains also of
recurrent epistaxis of varying intensity ever since his childhood. Routine laboratory
tests showed mild anemia and iron deficiency (hemoglobin 11.9 g/dL; serum iron levels 56
mcg/dL), since there was no major bleeding in the past months.</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Angiomatous papules affecting the tongue</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0226-g01"/>
      </fig>
      <p>Mother (who died at age 45 due to stroke), sister and daughter have similar lesions.
Histology of nasal injury point to vascular dilation and deposition of hemosiderin
(<xref ref-type="fig" rid="f02">Figure 2</xref>).</p>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p><bold>A.</bold> Histology shows vascular dilation and pigment leakage (40 X
magnified); <bold>B.</bold> Erythrocytes in the center of the field (100 X
magnified)</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0226-g02"/>
      </fig>
      <p>Bronchoscopy, esophagogastroduodenoscopy and colonoscopy show diffuse telangiectasias
without signs of recent bleeding (<xref ref-type="fig" rid="f03">Figures 3</xref> and
<xref ref-type="fig" rid="f04">4</xref>). As the most serious complaint of the
patient was nose bleeding, he was referred to otolaryngology and is being monitored to
exclude other possible foci of AVMs.</p>
      <fig id="f03" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Esophagus: telangiectasias covering the entire mucosa without evidence of bleeding
in upper gastrointestinal endoscopy</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0226-g03"/>
      </fig>
      <fig id="f04" orientation="portrait" position="float">
        <label>FIGURE 4</label>
        <caption>
          <p>Stomach: angiomatous lesions visualized in all segments of the organ</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0226-g04"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Hereditary Hemorrhagic Telangiectasia presents mucocutaneous macular telangiectasia with
1 to 3 mm of diameter that, generally, appears 10 to 30 years after epistaxis episodes
(60% of patients). Palms and fingers are the only sites affected in 71% of patients,
lips and tongue in 66%. Twenty to 40% have complete cutaneous manifestations, compatible
with the present report, which met the four Cura&#xE7;ao criteria.</p>
      <p>Pulmonary manifestations include hemoptysis, hemothorax, right-to-left-shunting and
paradoxical emboli (venous circulation embolic event that reaches the systemic
circulation). These symptoms arise from AVMs and fistulas, present in 5-23% of patients.
The paradoxical embolism, found in 40-50% of patients, can cause transitory ischemic
events and strokes. In 8% of patients, massive pulmonary hemorrhage can occur. Other
symptoms include hypoxia, dyspnea, cyanosis, polycythemia and clubbing of the distal
phalange.</p>
      <p>Complications in the central nervous system (CNS) vary from transitory ischemic events
to an abscess or intracranial bleeding. It is estimated that 8-41% of patients with HHT
will present some neurological complication during their lifetime. Clinical
manifestations may include convulsions, headache, coma and different degrees of
neurological deficits.</p>
      <p>In the gastrointestinal tract, manifestations include telangiectasias, AVMs and
varicosities, which can lead to upper gastrointestinal bleeding, liver dysfunction and
encephalopathy. Bleeding tends to be recurrent and progressive, usually occurring after
40 years of age.<sup><xref rid="r01" ref-type="bibr">1</xref></sup></p>
      <p>The treatment traditionally relies on surgical procedures, preferably endoscopic, to
control iron deficiency anemia, bleeding and potentially lethal aneurysms, in addition
to the use of hormonal therapies (estrogen and progesterone).<sup><xref rid="r06" ref-type="bibr">6</xref>,<xref rid="r07" ref-type="bibr">7</xref></sup> In recent
research, bevacizumab (anti-VEGF monoclonal antibody) has been evaluated with promising
results, but it is still not considered definitive due primarily to its various
long-term side effects.<sup><xref rid="r04" ref-type="bibr">4</xref></sup></p>
      <p>Prognosis is favorable in cases where the bleeding can be controlled, and the reported
mortality due to disease complications is less than 10% of cases.</p>
      <p>Knowledge of dermatological aspects of this rare and potentially severe condition may be
essential for early diagnosis, enabling the investigation of pulmonary and CNS
malformations and preventing possible catastrophic effects of the disease.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p>Financial Support: None.</p>
      </fn>
      <fn fn-type="other">
        <p><bold>How to cite this article:</bold> Barbosa AB, Hans-Filho G, Vicari CFS, Medeiros
MZ, Couto DV, Takita LC. Rendu-Osler-Weber syndrome: dermatological approach. An Bras
Dermatol. 2015;90(3 Suppl 1):S226-8.</p>
      </fn>
      <fn fn-type="other" id="fn01">
        <label>*</label>
        <p>Work performed at the Servi&#xE7;o de Dermatologia Dr. G&#xFC;nter Hans N&#xFA;cleo de Hospital
Universit&#xE1;rio da Universidade Federal do Mato Grosso do Sul (NHUUFMS) - Campo Grande
(MS), Brazil.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garcia</surname>
              <given-names>RID</given-names>
            </name>
            <name>
              <surname>Cecatto</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Costa</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Veiga</surname>
              <given-names>FA</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Uvo</surname>
              <given-names>IP</given-names>
            </name>
            <name>
              <surname>Rapoport</surname>
              <given-names>PB</given-names>
            </name>
          </person-group>
          <article-title>S&#xED;ndrome de Rendu-Osler-Weber: tratamento cl&#xED;nico e
cir&#xFA;rgico</article-title>
          <source>Rev Bras Otorrinolaringol</source>
          <year>2003</year>
          <volume>69</volume>
          <fpage>577</fpage>
          <lpage>580</lpage>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dupuis-Girod</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bailly</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Plauchu</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Hereditary hemorrhagic telangiectasia: from molecular biology to
patient care</article-title>
          <source>J Thromb Haemost</source>
          <year>2010</year>
          <volume>8</volume>
          <fpage>1447</fpage>
          <lpage>1456</lpage>
          <pub-id pub-id-type="pmid">20345718</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sadick</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sadick</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>G&#xF6;tte</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Naim</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Riedel</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bran</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hereditary hemorrhagic telangiectasia: an update on clinical
manifestations and diagnostic measures</article-title>
          <source>Wien Klin Wochenschr</source>
          <year>2006</year>
          <volume>118</volume>
          <fpage>72</fpage>
          <lpage>80</lpage>
          <pub-id pub-id-type="pmid">16703249</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bose</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Holter</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Selby</surname>
              <given-names>GB</given-names>
            </name>
          </person-group>
          <article-title>Bevacizumab in hereditary hemorrhagic telangiectasia</article-title>
          <source>N Engl J Med</source>
          <year>2009</year>
          <volume>360</volume>
          <fpage>2143</fpage>
          <lpage>2144</lpage>
          <pub-id pub-id-type="pmid">19439755</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fuchizaki</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Miyamori</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kitagawa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kaneko</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kobayashi</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber
disease)</article-title>
          <source>Lancet</source>
          <year>2003</year>
          <volume>362</volume>
          <fpage>1490</fpage>
          <lpage>1494</lpage>
          <pub-id pub-id-type="pmid">14602446</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Juares</surname>
              <given-names>AJC</given-names>
            </name>
            <name>
              <surname>Dell'Aringa</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Nardi</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Kobari</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Rodrigues</surname>
              <given-names>VLMGM</given-names>
            </name>
            <name>
              <surname>Perches-Filho</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>
          <article-title>S&#xED;ndrome de Rendu-Osler-Weber: relato de caso e revis&#xE3;o de
literatura</article-title>
          <source>Rev Bras Otorrinolaringol</source>
          <year>2008</year>
          <volume>74</volume>
          <fpage>452</fpage>
          <lpage>457</lpage>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gontijo</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>LB</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>CMR</given-names>
            </name>
          </person-group>
          <article-title>Vascular malformations</article-title>
          <source>An Bras Dermatol</source>
          <year>2004</year>
          <volume>79</volume>
          <fpage>7</fpage>
          <lpage>25</lpage>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
